Sixty women with breast cancer (mean age: 61 years; range 36-78 years) were treated with Epirubicin (4’epi-Dox-orubicin), 60 mg m-2 , as single drug therapy. The drug was administered as 2 hours’ constant rate infusions. The pharmacokinetics of the drug during the first course of treatment was evaluated by measurements of the plasma concentration of Epirubicin at the end of the infusion period.
There was a five-fold inter-individual variation of the dose-normalized maximum plasma concentration, which increased with increasing age of the patients. There was no correlation between this pharmacokinetic parameter and degree of obesity.
An increase in maximum plasma concentration was associated with an increasing degree of alopecia (p = 0.025). Also the degree of nausea and vomiting showed a tendency to increase with increasing maximum plasma concentration (p = 0.07).
Fifty four of the sixty patients entered in the present study were evaluable for clinical response. There was one CR (complete remission). Seventeen patients achieved PR (partial response), and twenty five patients had SD (stable disease). Eleven patients did not respond to treatment.
The median maximum plasma concentrations were 322, 316, 336 and 288 ng ml-1 in patients with CR, PR, SD and PD, respectively.
The results in the present study showed that 60 mg m-2 of Epirubicin given as a constant rate infusion over 2 hours is a useful alternative to more aggressive combination drug therapy for the treatment of breast cancer.
Pharmacokinetics pirubicin 4’epi-Doxorubicin Infusion Side-effects Breast cancer
This is a preview of subscription content, log in to check access.
Mouridsen H T, Alfthan O, Bastholt L, Bergh J, Dalmark M, Eksborg S, Hellsten S, Kjaer M, Peterson C, Skovsgard T, Sprensen J B, Tropé C, Aabo K: Current status of epirubicin (Farmorubicin) in the treatment of solid tumours.Acta Oncologia29, 257 (1990).CrossRefGoogle Scholar
Dixon A R, Robertson J F R, Athanassiou E, Jackson L, Blarney R W: Weekly Low Dosage Epirubicin in Advanced Breast Cancer.Eur J Cancer26, 847 (1990).PubMedGoogle Scholar
Legha S S, Benjamin R S, Mackay B, Ewer M, Wallace S, Valdivieso M, Rasmussen S L, Blumenschein G R, Freireich E J: Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion,Ann Int Med96, 133(1982).PubMedGoogle Scholar
Shapira J, Gotfried M, Lishner M, Ravid M: Reduced Cardiotoxicity of Doxorubicin by a 6-Hour Infusion Regime - A Prospective Randomized Evaluation.Cancer65, 870(1990).PubMedCrossRefGoogle Scholar
Fronczak A, Drzewoski J, Polakowski P: Comparative Studies of Doxorubicin and 4’-Epirubicin Effects on Cardiovascular System in Rabbits.Polish J Pharmacol Pharm41, 597 (1989).Google Scholar
Nielsen D, Jensen J B, Dombernowsky P, Munck O, Fogh J, Brynjolf I, Havsteen H, Hansen M: Epirubicin Cardiotoxicity — A Study of 135 Patients with Advanced Breast Cancer.J Clin Oncol8, 1806 (1990).PubMedGoogle Scholar
Lahtinen R, Kuikka J, Nousianen T, Uusitupa M, Länsimies E: Cardiotoxicity of Epirubicin and Doxorubicin -A Double-Blind Randomized Study.Eur J Haematol46, 301 (1991).PubMedCrossRefGoogle Scholar
Robert J, Illiadis A, Hoerni B, Cano J-P, Durand M, Lagarde C: Pharmacokinetics of Adriamycin in patients with breast cancer: correlation between pharmacokinetic parameters and clinical short-time response.Eur J Cancer Clin Oncol18, 739(1982).PubMedCrossRefGoogle Scholar
Ratain M J, Robert J, van der Vijgh W J F: Limited Sampling Models for Doxorubicin Pharmacokinetics.J Clin Oncol9, 871(1991).PubMedGoogle Scholar
Eksborg S: Anthracycline pharmacokinetics. Limited samping model for plasma level monitoring with special reference to epirubicin (Farmorubicin).Acta Oncologia29, 339 (1990).CrossRefGoogle Scholar
Eksborg S, Ehrsson H: Liquid chromatography in anti-cancer drug research with special reference to anthraqui-none glycosides.J PharmBiomed Anal2, 297 (1984).CrossRefGoogle Scholar
Devine B J: Gentamicin therapy.Drug Intell Clin Pharm8, 650 (1974).Google Scholar
Daniel W W: Biostatistics:A foundation for analysis in the health sciences. John Wiley and Sons, Ins. New York (1983).Google Scholar
Brenner D E: Approaches to the problem of individual Doxorubicin dosing schedules.Path Biol35, 31 (1987).Google Scholar
Eksborg S, Strandler H-S, Edsmyr F, Näslund I, Tahvanainen P: Pharmacokinetic study of IV infusions of Adriamycin.Eur J Clin Pharmacol28, 205 (1985).PubMedCrossRefGoogle Scholar
Jakobsen P, Steiness E, Bastholt L, Dalmark M, Lorenzen A, Petersen A, Gjedde S B, Sandberg E, Rose C, Nielsen O S, Mouridsen H T, Jakobsen A: Multiple-Dose Pharmacokinetics of Epirubicin at Four Different Dose Levels: Studies in Patients with Metastatic Breast Cancer.Cancer Chemother Pharmacol28, 63 (1991).PubMedCrossRefGoogle Scholar
Morris R G, Kotasek D, Paltridge G: Disposition of Epirubicin and Metabolites with Repeated Courses to Cancer Patients.Eur J Clin Pharmacol40, 481 (1991).PubMedCrossRefGoogle Scholar
Eksborg S, Stendahl U, Lönroth U: Comparative pharmacokinetic study of Adriamycin and 4’epi-Adriamycin after their simultaneous intravenous administration.Eur J Clin Pharm30, 629 (1986).CrossRefGoogle Scholar
Eksborg S, Mattson: Pharmacokinetics of epirubicin in man. Non-influence of alpha interferon.Med Oncol Tumor Phannacother5, 131 (1988).Google Scholar
Eksborg S, Stendahl U, Antila K: Pharmacokinetics of 4’epi-Adriamycin after morning and afternoon intravenous administration.Med Oncol Tumor Pharmacother6, 195 (1989).PubMedGoogle Scholar
Robert J, Hoerni B: Age dependence of the early-phase pharmacokinetics of doxorubicin.Cancer Res43, 4467 (1983).PubMedGoogle Scholar
Rodvold K A, Rushing D A, Tewksbury D A: Doxorubicin clearance in the obese.J Clin Oncol6, 1321 (1988).PubMedGoogle Scholar
Robert J: Continuous infusion or intravenous bolus: What is the rational for doxorubicin administration?Cancer Drug Delivery4, 191 (1987).PubMedGoogle Scholar
Jakobsen P, Bastholt L, Dalmark M, Pfeiffer P, Petersen D, Gjebbe S B, Sandberg E, Rose C, Nielsen O S, Mouridsen H T: A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurement.Cancer Chemother Pharmacol28, 465 (1991).PubMedCrossRefGoogle Scholar
Stallard S, Morrison J G, George W D, Kaye S B: Distribution of Doxorubicin to Normal Breast and Tumour Tissue in Patients Undergoing Mastectomy.Cancer Chemother Pharmacol25, 286 (1990).PubMedCrossRefGoogle Scholar
Cumming J, McArdle C S: Studies on thein vivo disposition of Adriamycin in human tumours which exhibit different responses to the drug.Br J Cancer 53, 835 (1986).Google Scholar
Hryniuk W M, Figueredo A, Goodyear M: Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer.Seminars in Oncology14, (suppl 4) 3 (1987).PubMedGoogle Scholar
Habeshaw T, Paul J, Jones R, Stallard S, Stewart M, Kaye S B, Soukop M, Symonds R P, Reed N S, Rankin E M: Epirubicin At Two Dose Levels with Prednisolone as Treatment for Advanced Breast Cancer: The Results of a Randomized Trial.J Clin Oncol9, 295 (1991).PubMedGoogle Scholar
Bonneterre J: A Prospective Randomized Trial Comparing Epirubicin Monochemotherapy to Two Fluorouracil, Cyclophosphamide, and Epirubicin Regimens Differing in Epirubicin Dose in Advanced Breast Cancer Patients.J Clin Oncol9, 305(1991).Google Scholar
Carmo-Pereira J, Costa F O, Miles D W, Henriques E, Richards M A, Rubens R D: High-Dose Epirubicin as Primary Chemotherapy in Advanced Breast Carcinoma — A Phase-II Study.Cancer Chemother Pharmacol27, 394 (1991).PubMedCrossRefGoogle Scholar